中國平安(02318.HK):下半年投資市場仍波動 於新經濟投資已達7,000億人幣
中國平安(02318.HK)上半年投資收益按年微升0.4%至448.19億元人民幣(下同),集團首席投資執行官陳德賢表示,集團投資主要策略仍是拉長資產週期,使其與負債匹配,及防範跨週期風險。他指在2013年資產和負債之間缺口是8.3年,至去年底已縮短至4.1年。
他指,下半年金融市場及資產仍將波動,可提供投資機會,惟不確定因素包括新型肺炎疫情反覆,及通脹高於預期。未來將在債券投資以外增加更多投資種類,集團現時於新經濟的投資已達7,000億元,未來尚可投資的領域包括新能源、環保節能、碳中和及醫療健康等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.